Squarepoint
CATX icon

Squarepoint’s Perspective Therapeutics CATX Stock Holding History

Squarepoint’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-169,147
Closed -$705K – 4451
2026
Q1 		$705K Buy
+169,147
New +$715K ﹤0.01% 3062
2025
Q2 		– Sell
-32,569
Closed -$69.4K – 4538
2025
Q1 		$69.4K Sell
32,569
-163,639
-83% -$491K ﹤0.01% 4299
2024
Q4 		$626K Buy
+196,208
New +$1.6M ﹤0.01% 3523
2024
Q2 		– Sell
-2,899
Closed -$34.5K – 4105
2024
Q1 		$34.5K Buy
+2,899
New +$24.7K ﹤0.01% 3898
2021
Q1 		– Sell
-12,014
Closed -$54K – 3155
2020
Q4 		$54K Buy
12,014
+5,320
+79% +$23.5K ﹤0.01% 2799
2020
Q3 		$39K Buy
+6,694
New +$43.6K ﹤0.01% 2388

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Squarepoint's CATX Position: Q2 2026 in Review

Squarepoint sold out of Perspective Therapeutics (CATX) in Q2 2026, closing a stake of 169,147 shares — an estimated $705K sold.

Squarepoint first reported a position in CATX in Q3 2020 and held it in 6 quarters. The position peaked at $705K in Q1 2026. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Squarepoint reported no remaining Perspective Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Squarepoint sold 169,147 Perspective Therapeutics shares in Q2 2026, an estimated $705K.
  • Squarepoint first reported a position in Perspective Therapeutics in Q3 2020 and held it in 6 quarters.
  • Squarepoint's Perspective Therapeutics position peaked at $705K in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.